The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Open accessThe DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Abstract
Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)](https://figures.cochat.ai/paper-figures/47a9baa04bb54a408b711fbf0d4e6807/the-evolution-of-insulin-and-how-it-informs-therapy-and-treatment-choices-figure-2.jpg)
















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Towards a goal of reducing the need for multiple daily injections, the first long-acting insulin was developed in the 1930s by H. C. Hagedorn. It was a suspension protamine zinc insulin that was based on the discovery that insulin action could be prolonged by adding protamine obtained from river trout semen106. The action of protamine zinc insulin lasted 24–36 h.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These insulins reduce postprandial hyperglycemia but have otherwise not been shown to reduce HbA 1c or hypoglycemia to a greater extent than rapid-acting analogs (3).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“After injection and dilution of the phenolic preservative in the SC space, the dihexamers selfassociate, forming multihexamer complexes (60).”
BackgroundThe Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429 · cited 1×
“The fatty acyl side chain also enables binding to serum albumin, a long-lived plasma protein, thus slowing the disposition of detemir to peripheral tissues and clearance from the body (53).”
BackgroundBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 1×
“A 3-fold concentrated version of insulin glargine was developed to prolong the duration of action when the results of 2 preliminary studies showed less diurnal variation in glucose-lowering activity with U-300 compared to the same dose of U-100 glargine (46).”
ResultGlucose Sensing in Pancreatic β-Cells
Schuit, F. C., Huypens, P., Heimberg, H., & Pipeleers, D. G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.1 · Cited by 405
Human Insulin from Recombinant DNA Technology
Johnson, I. S. (1983) · Science · doi:10.1126/science.6337396 · Cited by 401
Cited by
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (“regular”) human insulin, resulting in reduced early pos…”
InfluentialSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationRole of Insulin in Health and Disease: An Update
Rahman, M. S., Hossain, K. S., Das, S., Kundu, S., Adegoke, E. O., Rahman, M. A., Hannan, M. A., Uddin, M. J., & Pang, M.-G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126403 · Cited by 472
“Exogenous insulins are now available in the form of rapidacting, short-acting, intermediate-acting, and long-acting [16].”
BackgroundHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
Self-citation100 years of insulin: celebrating the past, present and future of diabetes therapy
Sims, E. K., Carr, A. L. J., Oram, R. A., DiMeglio, L. A., & Evans-Molina, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01418-2 · Cited by 270
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 192
“Insulin can be given by syringe, pen (including “smart” pens), catheter connected to insulin pump or an insulin delivery device (continuous subcutaneous insulin injection), or more rarely by inhalation (92, 94, 100).”
BackgroundInfluentialDiabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
“Insulin is most widely known for its metabolic effects, but it also has important mitogenic effects [27,28].”
BackgroundTowards halal pharmaceutical: Exploring alternatives to animal-based ingredients
Herdiana, Y., Sofian, F. F., Shamsuddin, S., & Rusdiana, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23624 · Cited by 92
“Some examples include: 1) Insulin, porcine insulin is structurally similar to human insulin and is used as a replacement therapy for patients with diabetes [72].”
BackgroundRosenstock, J., Juneja, R., Beals, J. M., Moyers, J. S., Ilag, L. L., & McCrimmon, R. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnad037 · Cited by 92
“The first real breakthrough in addressing these challenges was the development of IGlar U100, an insulin analogue, which was approved in 2000 (1).”
InfluentialSelf-citationInsulin detection in diabetes mellitus: challenges and new prospects
Vargas, E., Nandhakumar, P., Ding, S., Saha, T., & Wang, J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00842-3 · Cited by 90
McAlister, E., Kirkby, M., Domínguez‐Robles, J., Paredes, A. J., Anjani, Q. K., Moffatt, K., Vora, L. K., Hutton, A. R. J., McKenna, P. E., Larrañeta, E., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.06.002 · Cited by 81
Basal weekly insulins: the way of the future!
Rosenstock, J., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154924 · Cited by 76
Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials
Kramer, C. K., Retnakaran, R. R., & Zinman, B. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.014 · Cited by 75
Lee, S., & Yoon, K. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0163 · Cited by 68
“During a century of insulin use, it has evolved and many different options are currently available through modification of its structure or formulation (Table 1) [37].”
BackgroundInfante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 66
Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein
Moyers, J. S., Hansen, R. J., Day, J. W., Dickinson, C. D., Zhang, C., Ruan, X., Ding, L., Brown, R. M., Baker, H. E., & Beals, J. M. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001105 · Cited by 66
“These basal insulin products include insulin glargine, insulin detemir, and insulin degludec (Hirsch et al., 2020).”
BackgroundSelf-citationIonically cross-linked alginate-chitosan core-shell hydrogel beads for oral delivery of insulin
Phan, V. H. G., Mathiyalagan, R., Nguyen, M.-T., Tran, T.-T., Murugesan, M., Ho, T.-N., Huong, H., Yang, D., Li, Y., & Thambi, T. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.165 · Cited by 65
Review: Glucose-sensitive insulin
Høeg-Jensen, T. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101107 · Cited by 58
An autonomous channel deep learning framework for blood glucose prediction
Yang, T., Yu, X., Ma, N., Wu, R., & Li, H. (2022) · Applied Soft Computing · doi:10.1016/j.asoc.2022.108636 · Cited by 56
Tasdemiroglu, Y., Gourdie, R. G., & He, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175192 · Cited by 50
Szunerits, S., Melinte, S., Barras, A., Pagneux, Q., Voronova, A., Abderrahmani, A., & Boukherroub, R. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00886a · Cited by 49
The promising future of insulin therapy in diabetes mellitus
Cheng, R., Taleb, N., Stainforth-Dubois, M., & RABASA-LHORET, R. P. R. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00608.2020 · Cited by 49
Estrada-Almeida, A. G., Castrejón-Godínez, M. L., Mussali-Galante, P., Tovar‐Sánchez, E., & Rodríguez, A. (2024) · Journal of Xenobiotics · doi:10.3390/jox14040082 · Cited by 49
Fralick, M., & Zinman, B. (2021) · Diabetologia · doi:10.1007/s00125-020-05371-6 · Cited by 44
“The production of human insulin essentially resolved the problem associated with the development of anti-insulin antibodies leading to lipoatrophy and antibody-mediated insulin resistance [31].”
Background100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?
Herman, W. H., & Kuo, S. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.09.001 · Cited by 43
Nkonge, K. M., Nkonge, D. K., & Nkonge, T. N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01468-4 · Cited by 42
“Between January and February 1922, insulin was successfully used to lower blood glucose levels and resolve glycosuria and ketonuria in a teenage boy living with diabetes mellitus (DM) [1, 2].”
BackgroundMethodMeasuring Insulin Resistance in Humans
Sharma, V. R., Matta, S. T., Haymond, M. W., & Chung, S. T. (2020) · Hormone Research in Paediatrics · doi:10.1159/000515462 · Cited by 42
Current Management of Glycemia in Children with Type 1 Diabetes Mellitus
Sperling, M. A., & Laffel, L. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2112175 · Cited by 42
Artificial Intelligence Algorithms for Treatment of Diabetes
Rashid, M. M., Askari, M. R., Chen, C., Liang, Y., Shu, K., & Çınar, A. (2022) · Algorithms · doi:10.3390/a15090299 · Cited by 41
“Many activities focus on improving the treatment of diabetes using various classes of pharmacological drugs and medical devices that can help improve the regulation of blood glucose concentrations (BGC) in people with diabetes [8–10].”
BackgroundInsulin: A 100-Year-Old Discovery With a Fascinating History
Rostène, W. H., & MEYTS, P. D. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab020 · Cited by 39
Progress in Simulation Studies of Insulin Structure and Function
Gorai, B., & Vashisth, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.908724 · Cited by 39
“Insulin was first used about 100 years ago to save a 14 year old boy who was suffering from type 1 diabetes mellitus (2).”
MethodA Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method
Sugumar, V., Ang, K. P., Al-Shanon, A. F., Sethi, G., Yong, P. V. C., Looi, C. Y., & Wong, W. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071406 · Cited by 37
“Detemir was approved for the market in June 2005 [28].”
BackgroundInfluentialFrom islet of Langerhans transplantation to the bioartificial pancreas
Berney, T., Wassmer, C., Lebreton, F., Bellofatto, K., Fonseca, L. M., Bignard, J., Hanna, R., Peloso, A., & Berishvili, E. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104139 · Cited by 36
A Century-long Journey From the Discovery of Insulin to the Implantation of Stem Cell–derived Islets
Ramzy, A., Belmonte, P. J., Braam, M. J. S., Ida, S., Wilts, E. M., Levings, M. K., Rezania, A., & Kieffer, T. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac021 · Cited by 34
Hyperglycemia-driven signaling bridges between diabetes and cancer
Ghareghomi, S., Arghavani, P., Mahdavi, M., Khatibi, A., García‐Jiménez, C., & Moosavi‐Movahedi, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116450 · Cited by 32
Diabetes mellitus: The pathophysiology as a canvas for management elucidation and strategies
Iheagwam, F. N., & Iheagwam, O. T. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100351 · Cited by 32
Islet transplantation-immunological challenges and current perspectives
Kabakchieva, P., Assyov, Y. S., Gerasoudis, S., Vasilev, G., Peshevska-Sekulovska, M., Sekulovski, M., Lazova, S., Miteva, D., Gulinac, M., Tomov, L., et al. (2023) · World Journal of Transplantation · doi:10.5500/wjt.v13.i4.107 · Cited by 31
Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs
Hulsebosch, S. E., Pires, J., Bannasch, M. J., Lancaster, T. M., Delpero, A. R., Ragupathy, R., Murikipudi, S., Zion, T. C., & Gilor, C. (2022) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16449 · Cited by 30
“To extend the duration of action, traditional insulin formulations typically rely on manipulation of the rate of hexamer dissociation in the SC depot to slow insulin absorption into the blood.(6) Furthermore, decreasing the affinity of insulin to its receptor also prolongs duration of action.”
BackgroundInfluentialRecent advancements on novel approaches of insulin delivery
Karmakar, S., Bhowmik, M., Laha, B., & Manna, S. (2023) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2023.100253 · Cited by 30
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 30
Xu, B., Liu, H., Yang, G., Zhang, S., Zhou, Z., & Gao, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125128 · Cited by 27
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Retnakaran, R. R., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14552 · Cited by 27
“Conversely, glargine U-300 requires a higher dose than U-100 for similar biologic action, which can be perceived as a disadvantage insofar as patients may be reluctant to take higher doses of insulin.(3)”
BackgroundNew Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
Discovery of Insulin is a Great Achievement for the Diabetes Patients
Mohajan, D., & Mohajan, H. K. (2023) · Studies in Social Science & Humanities · doi:10.56397/sssh.2023.08.02 · Cited by 26
Insulin analogs in the treatment of type II diabetes and future perspectives
Sebastian, S. A., Co, E. L., Mehendale, M., & Hameed, M. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101417 · Cited by 25
Reduction in Postprandial Peak Glucose With Increased Technosphere Insulin Dosage
Kaiserman, K. B., Christiansen, M. P., Bhavsar, S., Ulloa, J., Santogatta, B., Hanna, J., & Bailey, T. S. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221110622 · Cited by 24
“15,16 The extended duration of insulin activity following subcutaneous injection of RAA formulations (up to five hours) 17-19 can also increase hypoglycemia risk.”
BackgroundInfluentialBruijn, N., van Lohuizen, R., Boron, M., Fitzek, M. P., Gabriele, F., Giuliani, G., Melgarejo, L., Řehulka, P., Sebastianelli, G., Triller, P., et al. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01724-3 · Cited by 23
“They display distinct properties regarding their absorption, distribution, metabolism, elimination, and impact on blood glucose levels [133].”
BackgroundTrends in U.S. Insulin Use and Glucose Monitoring for People with Diabetes: 2009-2018
Perez-Nieves, M., Juneja, R., Fan, L., Meadows, E., Lage, M. J., & Eby, E. L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211028268 · Cited by 22
Self-citationShubow, S., Sun, Q., Phan, A. L. N., Hammell, D. C., Kane, M., Lyman, G. H., Gibofsky, A., Lichtenstein, G. R., Bloomgarden, Z. T., Cross, R. K., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2765 · Cited by 22
Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 20
“Initially, insulin was extracted from animal sources, primarily bovine and porcine pancreases,leadingtoissueswithimmunogenicityandvariability in efficacy [207].”
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05600-6 · Cited by 19
Self-citationFactors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review
Sparre, T., Hammershøy, L., Steensgaard, D. B., Sturis, J., Vikkelsøe, P., & Azzarello, A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221145201 · Cited by 18
The three-dimensional structure of insulin and its receptor
Forbes, B. E. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2022.12.001 · Cited by 18
Al‐Ozairi, E., Steenackers, N., Pazmiño, S., Alattar, A., Kandari, J. A., Almeda‐Valdés, P., Antonio‐Villa, N. E., Delfin, C., Faradji, R. N., García-Tuomola, A., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102869 · Cited by 18
“8 However, the improved ability to prevent the catabolic state that historically characterized people with type 1 diabetes has introduced new challenges, notably the increasing presence of obesity among this population.”
BackgroundCengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Codner, E., Ehtisham, S., Jarosz-Chobot, P., Mungai, L. N. W., Ng, S. M., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543169 · Cited by 17
2025 iCatCare consensus guidelines on the diagnosis and management of diabetes mellitus in cats
Taylor, S. S., Cannon, M., Church, D. B., Fleeman, L. M., Fracassi, F., Gilor, C., Mott, J., & Niessen, S. (2025) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x251399103 · Cited by 17
“Suspensions contain various additives (zinc for porcine lente, protamine for NPH and both for PZI), causing precipitation at the injection site, 88 slowing absorption and thus leading to a slower onset and longer duration of action. o ne disadvantage of these formulations is the need for even…”
Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
Haller, M. J., Jones, M. C., Bhavsar, S., & Kaiserman, K. B. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01368-7 · Cited by 16
Diabetes mellitus: 100 years since the discovery of insulin
Pοlyzos, S. A., & Mantzoros, C. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154737 · Cited by 16
An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats
Gilor, C., Hulsebosch, S. E., Pires, J., Bannasch, M. J., Lancaster, T. M., Delpero, A. R., Ragupathy, R., Murikipudi, S., & Zion, T. C. (2021) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16150 · Cited by 16
Biopharmaceutical nanoclusters: Towards the self-delivery of protein and peptide therapeutics
Danielsen, M., Hempel, C., Andresen, T. L., & Urquhart, A. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.050 · Cited by 16
Amyloidogenicity of peptides targeting diabetes and obesity
Lima, L. M. T. R., & Icart, L. P. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112157 · Cited by 16
Tardo, A. M., Fleeman, L. M., Fracassi, F., Berg, A. S., Guarino, A. L., & Gilor, C. (2024) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17106 · Cited by 15
Vasileva, L. A., Gaynanova, G. A., Romanova, E. A., Petrov, K. A., Feng, C., Zakharova, L. Y., & Sinyashin, O. G. (2024) · Russian Chemical Reviews · doi:10.59761/rcr5150 · Cited by 15
Ayan, E. B., & DeMirci, H. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220610150342 · Cited by 15
C., J. L. D., Colmegna, P. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0468 · Cited by 15
“Considering that new insulin formulations focus on increasing availability and diffusion of insulin monomers, for example using vasodilation, 35,36 we penalize deviations of the estimated rate of absorption of insulin in the second compartment into plasma ( k a 2 ) from its original probability…”
Liu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Understanding the principles of insulin use in type 1 and type 2 diabetes management
Smyth, T. (2020) · Nursing Standard · doi:10.7748/ns.2020.e11677 · Cited by 14
One hundred years of insulin: Is it time for smart?
Gilor, C., & Fleeman, L. M. (2022) · Journal of Small Animal Practice · doi:10.1111/jsap.13507 · Cited by 13
A centennial review of discoveries and advances in diabetes: Children and youth
Mistry, S., Tonyushkina, K. N., Benavides, V. C., Choudhary, A., Huerta‐Saenz, L., Patel, N. S., Mahmud, F. H., Libman, I. M., & Sperling, M. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13392 · Cited by 14
Treatment of Diabetes Mellitus in Children and Adolescents
Yau, M., & Sperling, M. A. (2021) · Cited by 12
Ahn, D. T. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211062624 · Cited by 12
Porcine And Bovine-Derived Ingredients: Islamic Rules in Halal Pharmaceutical Products
Maifiah, M. H. M., & Ismail, W. N. E. S. W. (2023) · Journal of Fatwa Management and Research · doi:10.33102/jfatwa.vol28no3.549 · Cited by 12
“In consequence, the use of animal insulin is declining and has been replaced with human insulin (Hirsch et al., 2020).”
BackgroundIngrasciotta, Y., Vitturi, G., & Trifirò, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072113 · Cited by 11
“Over the past 40 years, various recombinant insulin analogues have been developed, employing distinct technologies tailored to achieve specific objectives, such as the use of rapid-release or extended-release formulations [6].”
BackgroundContinuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Stapled peptides as potential therapeutics for diabetes and other metabolic diseases
Nielipinska, D., Rubiak, D., Pietrzyk‐Brzezinska, A. J., Małolepsza, J., Błażewska, K. M., & Gendaszewska‐Darmach, E. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117496 · Cited by 10
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
“Especially with the use of long-acting analogues replacing neutral protamine Hagedorn (NPH) insulin, that is not generally required today [23].”
Self-citationCurrent Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
“The active form of insulin is created when zinc-stabilized hexamers, which are the form of insulin stored in pancreatic cells, are released from the cells and split into monomers (Hirsch et al. 2021).”
Chen, F., Mangano, K. M., Garelnabi, M., Cardaleen, K., & Tucker, K. L. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.04.005 · Cited by 10
Hamrick, C., & Chen, G. (2021) · Journal of Future Foods · doi:10.1016/j.jfutfo.2021.08.001 · Cited by 10
Formation of subvisible particles in commercial insulin formulations
Silva-Jr, H., de Araújo, T. S., Almeida, M. S., Scapin, S. M. N., & Lima, L. M. T. R. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112566 · Cited by 10
Celebration of a century of insulin therapy in children with type 1 diabetes
Rogol, A. D., Laffel, L. M., Bode, B. W., & Sperling, M. A. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2022-323975 · Cited by 10
Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus
Aktaş, G., & Duman, T. T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2320631 · Cited by 10
“Insulin Detemir, along with Glargine U-100, one of the first generations of a long-acting basal insulin analogue, has a half-life of approximately 5–7 hours and a duration of action of up to 24 hours [5,30–32].”
BackgroundCharting the next century of insulin replacement with cell and gene therapies
Lau, H. H., Gan, S. U., Lickert, H., Shapiro, A. M. J., Lee, K., & Teo, A. K. K. (2021) · Med · doi:10.1016/j.medj.2021.09.001 · Cited by 10
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
Colmegna, P. H., C., J. L. D., Garcia‐Tirado, J., DeBoer, M. D., & Breton, M. D. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221140401 · Cited by 9
“4,5 Several studies have demonstrated potential glycemic benefits of using faster insulins like fast-acting insulin Aspart (Fiasp) 6,7 or ultra-rapid lispro (URLi).”
BackgroundImplementing a choose your own adventure activity to improve insulin decision making
Litten, K. P., & Stewart, M. P. (2023) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2023.02.020 · Cited by 9
Editorial: Bone health in type 1 and type 2 diabetes: current knowledge and future direction
Shah, V. N. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000643 · Cited by 9
Diabetes and the WHO Model List of Essential Medicines
Khan, F. N., & Hirsch, I. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00318-1 · Cited by 9
Self-citationComplex Peptide Injectables: Development and Challenges
Vinukonda, A., Rapolu, K., Jadi, R. K., & Devadasu, V. R. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10710-5 · Cited by 8
“CPIs can have various therapeutic purposes, such as hormone regulation (Hirsch et al. 2020), cancer treatment (Nhàn et al. 2023), osteogenesis and bone remodeling (Toosi and Behravan 2020), cosmetic applications etc(Zhang et al. 2020).”
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners
Kesavadev, J., Basanth, A., Shankar, A., Saboo, B., Mohan, A. R., Joshi, S., Ghosh, S., Krishnan, G., Jothydev, K., & Ashik, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03250-3 · Cited by 8
“The aspartic acid substitution does not alter the receptor-binding region of the insulin molecule, so the biological activity of insulin aspart remains unaffected in vivo [31–33].”
Zhu, D., Ma, J., Wang, W., Shi, B., Dong, X., Bian, F., Li, Q., Wang, Y., Jiang, C., Wang, X., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06593-2 · Cited by 8
Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
Pedersen‐Bjergaard, U., Fabricius, T. W., & Thorsteinsson, B. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1970136 · Cited by 8
Broeng‐Mikkelgaard, S., Brøsen, J. M. B., Kristensen, P. L., Thorsteinsson, B., & Pedersen‐Bjergaard, U. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1301931 · Cited by 7
Yin, Y., Zhao, Z., Na, J., Xue, C., & Qin, K. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107998 · Cited by 7
Evolution of insulin therapy: past, present, future
Куркин, Д. В., Bakulin, D. A., Robertus, A. I., Kolosov, Y. A., Сергеевич, К. И., Morkovin, E. I., Strygin, A. V., Gorbunova, Y. V., Макаренко, И. Е., Васильевич, Д. Р., et al. (2024) · Problems of Endocrinology · doi:10.14341/probl13251 · Cited by 7
“Учитывая сравни-тельно короткую продолжительность действия, детемир часто вводят дважды в день для обеспечения устойчиво-го покрытия потребности в базальном инсулине [15].”
Biotechnology Revolution Shaping the Future of Diabetes Management
Kundnani, N. R., Lolescu, B. M., Dinu, A. R., Berceanu-Vaduva, D. M., Dumitrescu, P., Tamaș, T.-P., Sharma, A., & Popa, M.-D. (2024) · Biomolecules · doi:10.3390/biom14121563 · Cited by 7
Recreating the Endocrine Niche: Advances in Bioengineering the Pancreas
Fonseca, L. M., Krause, N., Lebreton, F., & Berishvili, E. (2025) · Artificial Organs · doi:10.1111/aor.14950 · Cited by 7
The Noble and Often Nobel Role Played by Insulin-Focused Research in Modern Medicine
Harrison, V. S., Khan, M. H., Chamberlain, C. E., & Harlan, D. M. (2021) · Diabetes Care · doi:10.2337/dci21-0012 · Cited by 7
Thammakosol, K., Vongtangton, P., Numthavaj, P., Auttara‐atthakorn, A., & Sriphrapradang, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70276 · Cited by 6
“29 While the incidence of hypokalemia did not differ significantly between groups in the pooled analysis, a trend towards increased hypokalemia was observed in the early basal insulin group, independent of insulin type.”
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetes Care · doi:10.2337/dci26-0122 · Cited by 6
Self-citation
Metadata
- Authors
- Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E.
- Affiliations
- University of Washington (US)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California
- Charlotte Area Health Education Center, Charlotte, North Carolina
- Corresponding author
- Hirsch, Irl B
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-05-12
- Volume
- 41
- Issue
- 5
- Pages
- 733-755
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7366348
- OpenAlex
- W3024580742
- Cited by
- 237
- References
- 82
- Citations by year
- 2026: 25 · 2025: 50 · 2024: 37 · 2023: 37 · 2022: 45 · 2021: 38 · 2020: 4
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- insulin, insulin formulations, insulin analogues, rapid-acting insulin, long-acting insulin, short-acting insulin, intermediate-acting insulin, insulin mixtures, insulin levels, pharmacokinetics, pharmacodynamics, endogenous insulin, diabetes treatment, insulin replacement therapy
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.